Great Novel Therapeutics Biotech & Medicals Corp.

As of June 30, 2026, Great Novel Therapeutics Biotech & Medicals Corp. carries a market capitalization of 2.11B, placing it among publicly traded companies globally. Its enterprise value stands at 1.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Great Novel Therapeutics Biotech & Medicals Corp. has 52.92M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Great Novel Therapeutics Biotech & Medicals Corp. maintains a current ratio of 26.62, meaning it holds 26.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Great Novel Therapeutics Biotech & Medicals Corp.'s stock has gained approximately 105.14% over the past 52 weeks. The 50-day moving average sits at 70.24, while the 200-day moving average is 48.05.

As of June 30, 2026, Great Novel Therapeutics Biotech & Medicals Corp. holds 698.97M in cash and equivalents against 6.44M in total debt, resulting in a net debt position of -75.81M. Total book value stands at 753.63M, with working capital of 697.20M providing operational flexibility.

Great Novel Therapeutics Biotech & Medicals Corp.'s most recent stock split took place on January 21, 2026 with a 303:319 split ratio.